Feb 1, 2020 · The Hans algorithm employs IHC for CD10, BCL6, and IRF4/MUM1 to predict either germinal center or activated B-cell phenotype . These markers are each considered positive if 30% or more of lymphoma cells are positive.

May 24, 2022 · The morphologic, immunophenotypic and cytogenetic findings are diagnostic of diffuse large B cell lymphoma, NOS, GCB subtype (Hans algorithm).

Aug 31, 2009 · Purpose: Hans and coworkers previously developed an immunohistochemical algorithm with ∼80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell–like (GCB) and activated B-cell–like (ABC) subtypes.

Algorithms developed by Hans et al., using immunohistochemistry was first widely accepted as a mechanism to divide DLBCL into germinal centre (GC) and non-GC subtypes.11 The algorithm is based on IHC expressions of CD10 (Cluster of Differentiation 10), BCL6 (B Cell Lymphoma 6) and MUM1(Multiple Myeloma 1) proteins.

The classic Hans algorithm utilized antibodies against CD10, BCL6 and MUM-1/IRF4. 14 With the development of new IHC antibodies, the panel has been expanded in newer iterations known as “Choi”, “Tally” and “Visco-Young” algorithms. 15–17 The degree to which the IHC categorizations, ABC vs. GCB, correlate with COO as defined by GEP ...

Mar 13, 2025 · The Hans algorithm follows a structured approach to classify DLBCL based on immunohistochemical marker expression. The process begins with selecting representative tumor tissue, usually obtained through biopsy and preserved in …

The Hans algorithm is a tool used by pathologists to classify diffuse large B cell lymphoma (DLBCL) into different subtypes based on the expression of specific proteins in the cancer cells.

Introduction: In recent years, "double hit" and "double protein" involving gene rearrangement and protein expression of c-MYC and BCL2 and/or BCL6 are the most used terms to describe poor prognostic factors in diffuse large B-cell lymphoma (DLBCL).

Mar 3, 2021 · The Hans algorithm is as follows: GCB: CD10+ or CD10−BCL6+MUM1−; non-GCB: CD10−BCL6−MUM1+ or CD10−BCL6+MUM1+ or CD10−BCL6−MUM1−. ‡

Hans algorithm subclassified DLBCL into prognostically distinct molecular subtypes by using immunohistochemistry (IHC). Fine-needle aspiration biopsy cytology (FNABC) is a first-line diagnostic modality in lymphadenopathy.